# Lupus Erythematosus, Systemic; Lupus Nephritis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/lupus-erythematosus-systemic-lupus-nephritis

> 4 upcoming FDA catalysts in lupus Erythematosus, Systemic; Lupus Nephritis: rapcabtagene autoleucel (NVS) on Feb to May 2028 (topline data readout); rapcabtagene autoleucel (NVS) on February 2028 (primary completion); zola-cel (BMY) on May to Aug 2028 (topline data readout); zola-cel (BMY) on May 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb to May 2028 | [Rapcabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT06581198 (A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06581198)) |
| February 2028 | [Rapcabtagene autoleucel primary completion](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT06581198 (A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06581198)) |
| May to Aug 2028 | [Zola-cel topline data readout](https://sec-api.dev/pdufa/zola-cel) | BMY | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT07015983 (A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-05-17 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015983)) |
| May 2028 | [Zola-cel primary completion](https://sec-api.dev/pdufa/zola-cel) | BMY | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT07015983 (A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-05-17 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015983)) |

## Drugs

- [Rapcabtagene autoleucel](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) (NVS)
- [Zola-cel](https://sec-api.dev/pdufa/zola-cel) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/lupus-erythematosus-systemic-lupus-nephritis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lupus Erythematosus, Systemic; Lupus Nephritis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/lupus-erythematosus-systemic-lupus-nephritis

```bibtex
@misc{secapidev_indications_lupus_erythematosus_systemic_lupus_nephritis_20261116,
  title        = {Lupus Erythematosus, Systemic; Lupus Nephritis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/lupus-erythematosus-systemic-lupus-nephritis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_lupus_erythematosus_systemic_lupus_nephritis_20261116","title":"Lupus Erythematosus, Systemic; Lupus Nephritis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/lupus-erythematosus-systemic-lupus-nephritis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
